Investor Interest Coming Back to Biotech

Healthcare >> Analyst Interviews >> March 19, 2018

John Vandermosten, CFA, is a senior biotechnology research analyst for Zacks SCR where he covers a portfolio of small-cap equities. His background includes 20 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. Formerly, Mr. Vandermosten was a research analyst for Singular Research covering the health care space and a consultant with Coker Group, a national health care services firm providing financial services to health care organizations. At Coker Group he consulted with clients in a variety of strategic and financial areas, including asset valuations, due diligence and transactions. Prior to his role as sell-side analyst and consultant, Mr. Vandermosten was a portfolio manager at Westwood Holdings Group and covered health care and other spaces as a research analyst. Mr. Vandermosten was also an analyst at the Teacher Retirement System of Texas. Mr. Vandermosten has an MBA from Texas A&M University, an M.A. from Tulane University and a B.A. from San Diego State University. He has also earned the Chartered Financial Analyst (CFA) designation and is a member of the CFA Society of Dallas. Profile

TWST: What is your coverage currently?

Mr. Vandermosten: I cover small-cap biotechnology stocks with market caps from 10 million to several hundreds of million of dollars. I focus on

Join for free to read a longer excerpt or purchase this article

Investor Interest Coming Back to Biotech

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Investor Interest Coming Back to Biotech

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS